CA3233571A1 - Combinations of kras g12d inhibitors with irinotecan and related methods of treatment - Google Patents

Combinations of kras g12d inhibitors with irinotecan and related methods of treatment Download PDF

Info

Publication number
CA3233571A1
CA3233571A1 CA3233571A CA3233571A CA3233571A1 CA 3233571 A1 CA3233571 A1 CA 3233571A1 CA 3233571 A CA3233571 A CA 3233571A CA 3233571 A CA3233571 A CA 3233571A CA 3233571 A1 CA3233571 A1 CA 3233571A1
Authority
CA
Canada
Prior art keywords
kras
irinotecan
pharmaceutically acceptable
inhibitor
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3233571A
Other languages
English (en)
French (fr)
Inventor
Jill HALLIN
James Gail Christensen
Vickie BOWCUT
Peter Olson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirati Therapeutics Inc
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of CA3233571A1 publication Critical patent/CA3233571A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3233571A 2021-10-05 2022-10-04 Combinations of kras g12d inhibitors with irinotecan and related methods of treatment Pending CA3233571A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163252405P 2021-10-05 2021-10-05
US63/252,405 2021-10-05
PCT/US2022/045625 WO2023059600A1 (en) 2021-10-05 2022-10-04 Combinations of kras g12d inhibitors with irinotecan and related methods of treatment

Publications (1)

Publication Number Publication Date
CA3233571A1 true CA3233571A1 (en) 2023-04-13

Family

ID=85803676

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3233571A Pending CA3233571A1 (en) 2021-10-05 2022-10-04 Combinations of kras g12d inhibitors with irinotecan and related methods of treatment

Country Status (10)

Country Link
US (1) US20250249003A1 (cg-RX-API-DMAC7.html)
EP (1) EP4412720A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024537137A (cg-RX-API-DMAC7.html)
KR (1) KR20240073115A (cg-RX-API-DMAC7.html)
CN (1) CN118354794A (cg-RX-API-DMAC7.html)
AU (1) AU2022361219A1 (cg-RX-API-DMAC7.html)
CA (1) CA3233571A1 (cg-RX-API-DMAC7.html)
IL (1) IL311863A (cg-RX-API-DMAC7.html)
MX (1) MX2024004214A (cg-RX-API-DMAC7.html)
WO (1) WO2023059600A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
KR20260110993A (ko) 2023-10-09 2026-07-14 인사이트 코포레이션 Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
US20260137674A1 (en) 2024-10-23 2026-05-21 Incyte Corporation Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
WO2026090333A1 (en) 2024-10-23 2026-04-30 Incyte Corporation Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2017172678A1 (en) 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation

Also Published As

Publication number Publication date
JP2024537137A (ja) 2024-10-10
IL311863A (en) 2024-06-01
EP4412720A4 (en) 2025-08-13
MX2024004214A (es) 2024-07-29
WO2023059600A1 (en) 2023-04-13
CN118354794A (zh) 2024-07-16
KR20240073115A (ko) 2024-05-24
EP4412720A1 (en) 2024-08-14
US20250249003A1 (en) 2025-08-07
AU2022361219A1 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
AU2019392683B2 (en) Combination therapies
US12527795B2 (en) Compositions of adagrasib and mTOR inhibitors and methods of treatment therewith
US20250249003A1 (en) Combinations of kras g12d inhibitors with irinotecan and related methods of treatment
EP3849537B1 (en) Combination therapies
EP4412718A1 (en) Combination therapies of kras g12d inhibitors with sos1 inhibitors
WO2023059598A1 (en) Combination therapies of kras g12d inhibitors with shp-2 inhibitors
US20240408098A1 (en) COMBINATIONS OF KRAS G12D INHIBITORS WITH PI3Ka INHIBITORS AND RELATED METHODS OF TREATMENT
US20250108055A1 (en) Combination therapies
EP4552631A2 (en) Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer
US20250177410A1 (en) Combination therapies comprising a sos1 inhibitor and an egfr inhibitor
US20260102401A1 (en) Combination Therapies
HK40108579A (en) Combinations of kras g12d inhibitors with irinotecan and related methods of treatment
HK40108895A (en) Combinations of kras g12d inhibitors with pi3ka inhibitors and related methods of treatment
CN108245515A (zh) 多取代异喹啉衍生物的合成及其应用

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240904

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240904

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240904

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250902

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250902